Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep to Present at Investor Conferences (ASX:IMM)

SYDNEY, AUSTRALIA – 20 May 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related imm...read more

Next Science - Oraderm Pharmaceuticals appointed as BlastX distributor (ASX:NXS)

Sydney, Australia, Thursday, 19 May 2022: Next Science Limited (ASX:NXS) (Next Science) is pleased to announce that it has signed a multi-year distribution agreement for Australia and New Zealand wi...read more

Immutep - Leading Oncologists appointed to Clinical Advisory Board (ASX:IMM)

SYDNEY, AUSTRALIA – 18 May 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related imm...read more

Hygrovest agrees to divest its investment in Entourage Health (ASX:HGV)

Hygrovest Limited (ASX:HGV) ("HGV") is an Australian-listed specialist investment company which concentrates on producing capital growth for shareholders over the medium term from investme...read more

INOVIQ Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

Immutep - New & significant data from AIPAC phase 2b trial in MBC (ASX:IMM)

* Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in th...read more

LBT Innovations - Direct Sale of APAS Independence in United States (ASX:LBT)

Adelaide, Australia, 3 May 2022: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligenc...read more

INOVIQ - Australian Patent Granted for SubB2M Technology (ASX:IIQ)

* AU Patent No 2017358401 granted covering the SubB2M technology * Provides IP protection in Australia for SubB2M-based diagnostics INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) announc...read more

INOVIQ Key Manufacturing Agreement to Advance SubB2M tests (ASX:IIQ)

* INOVIQ has executed a Master Manufacturing Agreement with MP Biomedicals for production of the SubB2M protein for the Company’s SubB2M-based tests * INOVIQ’s SubB2M technology detects...read more

LBT Innovations - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:LBT)

Adelaide, Australia, 29 April 2022: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intellig...read more

TALi Digital - Company Update & Appendix 4C (ASX:TD1)

Highlights * Placement and Entitlement Offer raise $3.22M * CMO appointed in April and then as Interim CEO * First co-development payment received in April 2022 from U.S. partner, Akili * Indi...read more

INOVIQ Appendix 4C & Quarterly Activities Report - March 2022 (ASX:IIQ)

* Collaboration with the University of Queensland (UQ) expanded to develop a worldfirst exosome-based ovarian cancer screening test * ResearchDx, a US-based specialty contract diagnostics organisat...read more

TALi Digital - Notice of Extraordinary General Meeting/Proxy Form (ASX:TD1)

Notice is given that an Extraordinary General Meeting of Shareholders (EGM) of TALi Digital Limited ACN 108 150 750 (TALi or the Company) will be held on Tuesday, 28 June 2022 at 11.00 a.m. (Melbour...read more

TALi Digital - Extraordinary General Meeting Letter to Shareholders (ASX:TD1)

TALi Digital Ltd (ASX: TD1) advises that an Extraordinary General Meeting (“EGM”) of Shareholders will be held on Tuesday, 28 June 2022 at 11:00 a.m. (Melbourne time) as a virtual meetin...read more

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

Highlights * Signed Letter of Intent (LOI) with GenesisCare to support Radiopharm’s first Phase 1 trial in Australia * Entered supply agreement with TerraPower for access to Actinium-225, ...read more

Viewing: 1 - 15 of 200 Previous | Next